Hoechst Pakistan Limited

HPL

PK0021801011

Pharmaceuticals

End-of-day quote Pakistan S.E. Other stock markets 23:00:00 21/05/2024 BST			5-day change	1st Jan Change
1,370 ^PKR	-2.16%		-5.82%	+14.15%

04-24	Hoechst Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-18	Hoechst Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Sanofi - Aventis Pakistan Limited Announces Director Changes

April 23, 2019

Sanofi - Aventis Pakistan Limited informed Pakistan Stock Exchange that Ms. Naira Adamyan has been appointed as Director with effect from April 23, 2019 in place of David Khougazian.

Latest news about Hoechst Pakistan Limited

Hoechst Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	04-23	CI
Hoechst Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-17	CI
Hoechst Pakistan Limited Announces Company Secretary Changes	11-01	CI
Hoechst Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-01	CI
Sanofi-aventis Pakistan Limited will Change its Name to Hoechst Pakistan Limited	05/09/23	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	28/08/23	CI
Sanofi-aventis Pakistan Limited Announces CEO Changes	13/06/23	CI
Sanofi-aventis Pakistan Limited Announces Retirement of Dr. Asim Jamal as Managing Director, Effective June 30, 2023	13/06/23	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	29/05/23	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2022	02/05/23	CI
Sanofi Aventis Pakistan Limited Announces Change of Directors	01/05/23	CI
The Investor Consortium comprised of Packages Limited, IGI Investments Limited and Ali Gohar & Co. Ltd completed the acquisition of 52.87% stake in sanofi-aventis Pakistan Limited from Sanofi Foreign Participations B.V.	27/04/23	CI
Pakistan defers decision on drug price rise as pharma firms struggle	27/03/23	RE
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	29/10/22	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	01/09/22	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	29/04/22	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2021	31/03/22	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	27/10/21	CI
Sanofi-Aventis Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2021	28/04/21	CI
Sanofi-Aventis Pakistan Limited Recommends Final Cash Dividend for the Year Ended December 31, 2020	02/03/21	CI
Sanofi-Aventis Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2020	02/03/21	CI
Sanofi-Aventis Pakistan Limited Reports Earnings Results for the Third Quarter Ended September 30, 2020	27/10/20	CI
Sanofi-Aventis Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2020	29/04/20	CI
Sanofi-Aventis Pakistan Limited Recommends Final Cash Dividend for the Year Ended December 31, 2019	03/03/20	CI
Sanofi-Aventis Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2019	03/03/20	CI

Chart Hoechst Pakistan Limited

Duration

Period

More charts

Hoechst Pakistan Limited is a pharmaceutical company. The Company is engaged in the manufacturing, selling and trading of pharmaceutical and related products. The Company offers solutions for various therapeutic areas, such as antibiotics, cardiology, diabetes, pain and allergy and others. Its patient programs address unmet needs around access and education across Pakistan to support people with diabetes. It provides and delivers therapeutic solutions for cardiovascular diseases (CVDs) and works with healthcare professionals to impart awareness and knowledge to patients who are at risk of developing heart diseases. Its products include ampoules, vials, tablets and capsules, and oral liquids. Its brands include Flagyl, Clexane, No-Spa, Lantus, Amaryl, Claforan, Haemaccel, Enterogermina, Plavix and Selsun Blue. Selsun Blue helps treat and prevent dandruff symptoms by targeting dandruff from the source and thus soothes irritated scalp, fights itch and controls visible flakes.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HOECHST PAKISTAN LIMITED	+14.15%	48.53M
ELI LILLY AND COMPANY	+37.74%	723B
NOVO NORDISK A/S	+32.22%	598B
JOHNSON & JOHNSON	-2.07%	364B
MERCK & CO., INC.	+20.25%	331B
ABBVIE INC.	+2.99%	288B
ASTRAZENECA PLC	+16.60%	244B
NOVARTIS AG	+9.77%	210B
ROCHE HOLDING AG	-5.15%	208B
AMGEN INC.	+7.43%	169B